Impact of Systemic Therapy and Recurrence Pattern on Survival Outcome After Radiofrequency Ablation for Colorectal Liver Metastases

Overview

Journal J Cancer

Specialty Oncology

Date 2016 Nov 24

PMID 27877209

Citations 1

Authors

Axel Stang

Marcello Donati

Hauke Weilert

Karl Jurgen Oldhafer

Affiliations

Soon will be listed here.

Abstract

Most patients undergoing radiofrequency ablation (RFA) of colorectal liver metastasases (CLM) develop disease recurrence, but little is known about the effect of recurrence patterns and/or systemic therapy on outcome. In this study, we examined the recurrence patterns and survival after systemic therapy plus RFA in patients with unresectable CLM without extrahepatic disease. The aims were to analyze the effect of recurrence patterns on survival and to assess the relative benefit contributed by systemic therapy and local ablation to disease control and patient outcome. From January 2002 to December 2012, 113 patients underwent RFA of liver-limited CLM after systemic therapy. Univariate and multivariate analyses for associations between clinical and/or treatment-related variables, recurrence-free survival (RFS), recurrence patterns, and overall survival (OS) were carried out. Of 113 patients, 105 (92.8%) had disease recurrence (median RFS: 6.1 months). Lower post-recurrence OS was observed after early (≤6 months) than after late recurrence (8.5 versus 24.0 months, p < 0.001). Recurrence sites were RFA-sites only (4.8%), liver-only (57.1%), lung-only (10.5%), or multiple (27.6%); the corresponding post-recurrence OS was 21, 19, 39, and 7 months (p < 0.001), respectively. Response to pre-RFA systemic therapy was the strongest predictor for OS (hazard ratio [HR] 5.28), RFS (HR 3.30), early (odds ratio [OR] 6.34) and multiple-site recurrence (OR 3.83) (p < 0.01), respectively; only responders achieved 5-year OS and RFS (29% and 12% versus 0% and 0% for non-responders, p < 0.001, respectively). Survival after RFA for liver-limited CLM is strongly linked to the timing and pattern of non-local disease recurrence. Local ablation efficacy is necessary but not sufficient to obtain long-term disease control. Effective pre-RFA systemic therapy does favourably affect the incidence, timing and patterns of recurrence and long-term survival and appears essential for the tailoring of RFA application to maximize patient benefit.

Citing Articles

Impact of Elevated Circulating Histones on Systemic Inflammation after Radiofrequency Ablation in Lung Cancer Patients.

Gu T, Wen T, Zhang Y, Zhang D, Hua H, Liu L Biomed Res Int. 2018; 2017:6894832.

PMID: 29457035 PMC: 5804403. DOI: 10.1155/2017/6894832.

References

Goasguen N, de Chaisemartin C, Brouquet A, Julie C, Prevost G, Laurent-Puig P . Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents. Int J Cancer. 2009; 127(5):1028-37. DOI: 10.1002/ijc.25114. View

Stang A, Oldhafer K, Weilert H, Keles H, Donati M . Selection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal. BMC Cancer. 2014; 14:500. PMC: 4099490. DOI: 10.1186/1471-2407-14-500. View

Knudsen A, Kannerup A, Mortensen F, Nielsen D . Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy. Acta Radiol. 2009; 50(7):716-21. DOI: 10.1080/02841850902991634. View

Wakai T, Shirai Y, Sakata J, Valera V, Korita P, Akazawa K . Appraisal of 1 cm hepatectomy margins for intrahepatic micrometastases in patients with colorectal carcinoma liver metastasis. Ann Surg Oncol. 2008; 15(9):2472-81. DOI: 10.1245/s10434-008-0023-y. View

Govaert K, van Kessel C, Lolkema M, Ruers T, Borel Rinkes I . Does Radiofrequency Ablation Add to Chemotherapy for Unresectable Liver Metastases?. Curr Colorectal Cancer Rep. 2012; 8(2):130-137. PMC: 3343230. DOI: 10.1007/s11888-012-0122-9. View

Cremolini C, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L . Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol. 2015; 26(6):1188-1194. DOI: 10.1093/annonc/mdv112. View

Pathak S, Jones R, Tang J, Parmar C, Fenwick S, Malik H . Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis. 2011; 13(9):e252-65. DOI: 10.1111/j.1463-1318.2011.02695.x. View

DAngelica M, Kornprat P, Gonen M, DeMatteo R, Fong Y, Blumgart L . Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol. 2010; 18(4):1096-103. DOI: 10.1245/s10434-010-1409-1. View

Clark M, Smith R . Liver-directed therapies in metastatic colorectal cancer. J Gastrointest Oncol. 2014; 5(5):374-87. PMC: 4173041. DOI: 10.3978/j.issn.2078-6891.2014.064. View

10.

Ruers T, Punt C, van Coevorden F, Pierie J, Borel-Rinkes I, Ledermann J . Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012; 23(10):2619-2626. PMC: 3457746. DOI: 10.1093/annonc/mds053. View

11.

Shady W, Petre E, Gonen M, Erinjeri J, Brown K, Covey A . Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center. Radiology. 2015; 278(2):601-11. PMC: 4734163. DOI: 10.1148/radiol.2015142489. View

12.

Kemeny N, Jarnagin W, Capanu M, Fong Y, Gewirtz A, DeMatteo R . Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol. 2010; 29(7):884-9. PMC: 3646323. DOI: 10.1200/JCO.2010.32.5977. View

13.

Gillams A, Goldberg N, Ahmed M, Bale R, Breen D, Callstrom M . Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013. Eur Radiol. 2015; 25(12):3438-54. PMC: 4636513. DOI: 10.1007/s00330-015-3779-z. View

14.

Wakai T, Shirai Y, Sakata J, Kameyama H, Nogami H, Iiai T . Histologic evaluation of intrahepatic micrometastases in patients treated with or without neoadjuvant chemotherapy for colorectal carcinoma liver metastasis. Int J Clin Exp Pathol. 2012; 5(4):308-14. PMC: 3365817. View

15.

Cardella J, Kundu S, Miller D, Millward S, Sacks D . Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol. 2009; 20(7 Suppl):S189-91. DOI: 10.1016/j.jvir.2009.04.035. View

16.

Lam V, Spiro C, Laurence J, Johnston E, Hollands M, Pleass H . A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol. 2011; 19(4):1292-301. DOI: 10.1245/s10434-011-2061-0. View

17.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

18.

Kingham T, Tanoue M, Eaton A, Rocha F, Do R, Allen P . Patterns of recurrence after ablation of colorectal cancer liver metastases. Ann Surg Oncol. 2011; 19(3):834-41. DOI: 10.1245/s10434-011-2048-x. View

19.

Ahmed M, Solbiati L, Brace C, Breen D, Callstrom M, Charboneau J . Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology. 2014; 273(1):241-60. PMC: 4263618. DOI: 10.1148/radiol.14132958. View

20.

Mayer R, Venook A, Schilsky R . Progress against GI cancer during the American Society of Clinical Oncology's first 50 years. J Clin Oncol. 2014; 32(15):1521-30. DOI: 10.1200/JCO.2014.55.4121. View